![LDTs: FDA Approves First NGS Residual Cancer Detection Test](https://www.g2intelligence.com/wp-content/uploads/2023/04/56181_G2_stock_2-1080x675.jpg)
LDTs: FDA Approves First NGS Residual Cancer Detection Test
From - National Intelligence Report
The FDA broke new ground by allowing marketing of Adaptive Biotechnologies' ClonoSEQ assay, a next generation sequencing (NGS)-based test for…
From - National Intelligence Report
The FDA broke new ground by allowing marketing of Adaptive Biotechnologies' ClonoSEQ assay, a next generation sequencing (NGS)-based test for…
From - Laboratory Industry Report
The swirl of autumn leaves has brought a swirl of diagnostic deals. Here's a recap of the key activity from…
From - Laboratory Industry Report
The G2 Power Panel provided attendees at the 36th annual Lab Institute (Oct. 24-26; Washington, D.C.) an opportunity to learn how some of…
From - G2 Compliance Advisor
Hospital systems are increasingly exploring joint ventures as a means to monetize some of the hospital outreach laboratory's assets without…
From - Laboratory Industry Report
Amid back to school season, companies were back to making diagnostic deals. Here's a recap of the key activity from…